Selected research
Industry Growth & Trends
Global Rufinamide Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Rufinamide market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Rufinamide is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Rufinamide is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Rufinamide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Rufinamide market include Eisai, Mylan, Glenmark Pharms and West-ward Pharms, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Rufinamide market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Rufinamide market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Rufinamide market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Rufinamide.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Rufinamide market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Rufinamide Market by Company
Eisai
Mylan
Glenmark Pharms
West-ward Pharms
Rufinamide Segment by Type
Tablets
Oral suspension
Rufinamide Segment by Application
Adults
Pediatric patients
Rufinamide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rufinamide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rufinamide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rufinamide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Rufinamide companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Tablets
- Oral suspension
Applications
- Adults
- Pediatric patients
Companies covered
- Eisai
- Mylan
- Glenmark Pharms
- West-ward Pharms
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Rufinamide Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Rufinamide Market Size by Region (2021-2032)
- 1.4.1 Global Rufinamide Market Size by Region (2021-2026)
- 1.4.2 Global Rufinamide Market Size by Region (2027-2032)
- 1.5 Key Regions Rufinamide Market Size (2021-2032)
- 1.5.1 North America Rufinamide Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Rufinamide Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Rufinamide Market Size Growth Rate (2021-2032)
- 1.5.4 South America Rufinamide Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Rufinamide Market Size Growth Rate (2021-2032)
2 Rufinamide Market by Type
- 2.1 Type Introduction
- 2.1.1 Tablets
- 2.1.2 Oral suspension
- 2.2 Global Rufinamide Market Size by Type
- 2.2.1 Global Rufinamide Market Size Overview by Type (2021-2032)
- 2.2.2 Global Rufinamide Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Rufinamide Market Size Forecasted by Type (2027-2032)
- 2.3 Global Rufinamide Market Size by Regions
- 2.3.1 North America Rufinamide Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Rufinamide Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Rufinamide Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Rufinamide Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Rufinamide Market Size Breakdown by Type (2021-2026)
3 Rufinamide Market by Application
- 3.1 Type Introduction
- 3.1.1 Adults
- 3.1.2 Pediatric patients
- 3.2 Global Rufinamide Market Size by Application
- 3.2.1 Global Rufinamide Market Size Overview by Application (2021-2032)
- 3.2.2 Global Rufinamide Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Rufinamide Market Size Forecasted by Application (2027-2032)
- 3.3 Global Rufinamide Market Size by Regions
- 3.3.1 North America Rufinamide Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Rufinamide Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Rufinamide Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Rufinamide Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Rufinamide Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Rufinamide Industry Trends
- 4.2 Rufinamide Industry Drivers
- 4.3 Rufinamide Industry Opportunities and Challenges
- 4.4 Rufinamide Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Rufinamide Revenue (2021-2026)
- 5.2 Global Rufinamide Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Rufinamide Key Company Headquarters & Area Served
- 5.4 Global Rufinamide Company, Product Type & Application
- 5.5 Global Rufinamide Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Rufinamide Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Rufinamide Players Market Share by Revenue in 2025
- 5.6.3 2025 Rufinamide Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Eisai
- 6.1.1 Eisai Company Information
- 6.1.2 Eisai Business Overview
- 6.1.3 Eisai Rufinamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Eisai Rufinamide Product Portfolio
- 6.1.5 Eisai Recent Developments
- 6.2 Mylan
- 6.2.1 Mylan Company Information
- 6.2.2 Mylan Business Overview
- 6.2.3 Mylan Rufinamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Mylan Rufinamide Product Portfolio
- 6.2.5 Mylan Recent Developments
- 6.3 Glenmark Pharms
- 6.3.1 Glenmark Pharms Company Information
- 6.3.2 Glenmark Pharms Business Overview
- 6.3.3 Glenmark Pharms Rufinamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Glenmark Pharms Rufinamide Product Portfolio
- 6.3.5 Glenmark Pharms Recent Developments
- 6.4 West-ward Pharms
- 6.4.1 West-ward Pharms Company Information
- 6.4.2 West-ward Pharms Business Overview
- 6.4.3 West-ward Pharms Rufinamide Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 West-ward Pharms Rufinamide Product Portfolio
- 6.4.5 West-ward Pharms Recent Developments
7 North America
- 7.1 North America Rufinamide Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Rufinamide Market Size by Country (2021-2026)
- 7.3 North America Rufinamide Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Rufinamide Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Rufinamide Market Size by Country (2021-2026)
- 8.3 Europe Rufinamide Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Rufinamide Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Rufinamide Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Rufinamide Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Rufinamide Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Rufinamide Market Size by Country (2021-2026)
- 10.3 South America Rufinamide Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Rufinamide Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Rufinamide Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Rufinamide Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst